351. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
- Author
-
Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, and Gongora C
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Animals, Camptothecin administration & dosage, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Drug Resistance, Neoplasm, Drug Synergism, ErbB Receptors, Gene Expression Regulation, Neoplastic, HCT116 Cells, Humans, Irinotecan, Mice, Niacinamide administration & dosage, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras), Sorafenib, Xenograft Model Antitumor Assays, ras Proteins genetics, ATP-Binding Cassette Transporters genetics, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy, Neoplasm Proteins genetics, Niacinamide analogs & derivatives, Phenylurea Compounds administration & dosage
- Abstract
Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure. Therefore, new treatment options are needed to improve survival of patients with irinotecan-refractory CRCs, particularly those bearing KRAS mutations that preclude the use of anti-EGFR therapies. In this study, we investigated whether sorafenib could reverse irinotecan resistance, thereby enhancing the therapeutic efficacy of routinely used irinotecan-based chemotherapy. We used both in vitro (the HCT116, SW48, SW620, and HT29 colon adenocarcinoma cell lines and four SN-38-resistant HCT-116 and SW48 clones) and in vivo models (nude mice xenografted with SN-38-resistant HCT116 cells) to test the efficacy of sorafenib alone or in combination with irinotecan or its active metabolite, SN-38. We have shown that sorafenib improved the antitumoral activity of irinotecan in vitro, in both parental and SN-38-resistant colon adenocarcinoma cell lines independently of their KRAS status, as well as in vivo, in xenografted mice. By inhibiting the drug-efflux pump ABCG2, sorafenib favors irinotecan intracellular accumulation and enhances its toxicity. Moreover, we found that sorafenib improved the efficacy of irinotecan by inhibiting the irinotecan-mediated p38 and ERK activation. In conclusion, our results show that sorafenib can suppress resistance to irinotecan and suggest that sorafenib could be used to overcome resistance to irinotecan-based chemotherapies in CRC, particularly in KRAS-mutated tumors., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF